FDA greenlights first Ebola Virus treatment
The Food and Drug Administration Oct. 14 approved Inmazeb for treating Zaire ebolavirus infection in adult and pediatric patients. The drug is a mixture of three monoclonal antibodies (atoltivimab, maftivimab and odesivimab-ebgn) that, when combined, target glycoprotein on the Ebola virus’ surface to block its attachment and entry into the human body.
“Today’s approval highlights the importance of international collaboration in the fight against Ebola virus,” said John Farley, M.D., MPH, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research. “The urgent need for advanced therapies to combat this infectious disease is clear, and today’s action is a significant step forward in that effort.”
Related News Articles
Headline
The Centers for Disease Control and Prevention Feb. 6 released an advisory about an outbreak of Ebola in Uganda caused by the Sudan virus disease. There…
Headline
As a precaution in response to the recent Ebola outbreak in Uganda, the Centers for Disease Control and Prevention and Department of Homeland Security Customs…
Headline
The Centers for Disease Control and Prevention today issued an advisory to remind U.S. clinicians of best practices for evaluating patients for suspected Ebola…
Headline
The Centers for Disease Control and Prevention today joined the global public health community in marking the end of the Ebola outbreak in the Democratic…
Headline
With Ebola outbreaks in the Democratic Republic of the Congo and Guinea, the Centers for Disease Control and Prevention is reminding U.S. health care personnel…
Headline
Health officials in Guinea Sunday declared an Ebola outbreak in the nation’s southeastern N’Zerekore prefecture after confirming three cases in the rural…